UBS Asset Management rebalances portfolio, increasing stakes in T-Mobile US and ExxonMobil.

For T-Mobile US, UBS Asset Management Americas’ distinct business unit not only raised its stake by 13.3%, but did so by purchasing an additional 582,964 shares—ending the quarter with 4,958,610 shares valued at about $1.01 billion. The report also notes insider Andre Almeida bought 5,097 shares at an average cost of $196.18 (total value about $999,929.46).
The T-Mobile US article adds that institutional investors and hedge funds collectively own 42.49% of the company’s stock, providing context for how broad the ownership base is beyond UBS’s position change.
For NetEase, the filings detail that UBS reduced its stake by 4.8% by selling 406,190 shares, leaving it with 8,144,927 shares worth about $1.12 billion. The report also provides market context, noting NTES opened at $125.82 and has a 12-month range of $106.06 to $159.55 (with hedge funds and other institutional investors owning 11.07%).
For ExxonMobil, UBS’s increase came from buying an additional 2,465,410 shares (to reach 15,997,332 shares). The report also frames market/credit context by stating XOM opened at $146.80 and lists company financial metrics including a debt-to-equity ratio of 0.13, a current ratio of 1.04, and that 61.80% of the stock is owned by institutional investors.
UBS Asset Management Americas boosted its ExxonMobil stake by 18.2% in Q1 2026, buying 2.46 million additional shares to reach roughly 16 million shares worth $1.93 billion, according to Fintel. At the same time, the firm raised its T-Mobile US position by 13.3% and trimmed its NetEase holding by 4.8%, signaling a deliberate shift from Chinese tech toward energy and telecom.
The moves were revealed in a 13F-HR filing on May 13, 2026, covering the first quarter. Taken together, they show UBS rotating capital into what analysts call
UBS added 2,465,410 ExxonMobil shares in Q1 2026, bringing its total to 15,997,332 shares valued at $1.93 billion. ExxonMobil opened at $146.80 on June 12, within its one-year range of $105.53 to $176.41, according to MarketBeat. The company carries a conservative debt-to-equity ratio of just 0.13 and a current ratio of 1.04, making it a relatively stable bet.
The timing is deliberate. Data centers powering the AI boom need vast amounts of electricity. That has made traditional energy giants like ExxonMobil surprisingly relevant to the AI story. UBS Global CIO Mark Haefele has called 2026 the
UBS raised its T-Mobile US position by 582,964 shares to 4,958,610 shares, now worth about $1.01 billion. The fund was not alone in its confidence. On May 1, T-Mobile Broadband Chief Andre Almeida bought 5,097 shares at $196.18 each — a $999,929 open-market purchase — according to Stock Titan. Insider buys of that size are rare and often signal executive confidence in the company's near-term outlook.
T-Mobile beat Q1 2026 earnings estimates by posting $2.27 EPS against a $2.01 consensus, according to MarketBeat. The carrier recently absorbed 4 million UScellular customers and has a satellite-to-cell partnership with SpaceX's Starlink. Analysts at LightShed Partners upgraded the stock to Buy, citing T-Mobile's use of AI for pricing and service expansion. Institutional investors now own 42.49% of TMUS shares.
UBS sold 406,190 NetEase shares in Q1 2026, trimming its stake by 4.8% to 8,144,927 shares worth $1.12 billion. NetEase opened at $125.82 and has traded between $106.06 and $159.55 over the past year. Only 11.07% of the stock is owned by institutional investors — far less than ExxonMobil's 61.80% — suggesting limited broad institutional demand.
The trim reflects growing unease about Chinese tech. Beijing blocked major NetEase game titles from receiving licenses for three straight months in early 2026, according to AASTOCKS Financial News. UBS held on to larger positions in Tencent and Alibaba, which it views as stronger paths to AI monetization in Asia. The NetEase cut fits a broader pattern of Western funds quietly reducing exposure to Chinese gaming.
UBS made only a tiny cut to its Danaher position — just 0.5%, or about 25,000 shares — leaving it with 5,011,061 shares worth $1.15 billion. Danaher beat Q1 2026 EPS estimates ($2.06 actual vs. $1.96 expected) but missed revenue targets. The shortfall came from weak demand at its Cepheid unit, which makes respiratory disease tests, according to Danaher Investor Relations.
CEO Rainer Blair described a
Publishers
20
Articles
18
Reach
38